Pablo Rodríguez-Viciana
University College London (UCL), London, UK
Following a BSc by the Universidad Autonoma of Madrid, Spain, PR-V completed his PhD thesis in Julian Downward’s laboratory at the ICRF in London, where his work resulted in the identification of PI3K as a direct target of RAS and showed that RAS can use multiple effectors to signal downstream. He then carried out post-doctoral studies in Frank McCormick’s lab at the University of California, San Francisco, where his work led to the identification of the SHOC2 phosphatase complex as a unique regulatory node required for efficient RAS-ERK pathway activation with properties of an attractive therapeutic target. In 2008 he returned to London as a group leader at the UCL Cancer Institute where a major focus of his group is to study the function of the SHOC2 phosphatase complex in the context of diseases such as cancer and RASopathies.
Following a BSc by the Universidad Autonoma of Madrid, Spain, PR-V completed his PhD thesis in Julian Downward’s laboratory at the ICRF in London, where his work resulted in the identification of PI3K as a direct target of RAS and showed that RAS can use multiple effectors to signal downstream. He then carried out post-doctoral studies in Frank McCormick’s lab at the University of California, San Francisco, where his work led to the identification of the SHOC2 phosphatase complex as a unique regulatory node required for efficient RAS-ERK pathway activation with properties of an attractive therapeutic target. In 2008 he returned to London as a group leader at the UCL Cancer Institute where a major focus of his group is to study the function of the SHOC2 phosphatase complex in the context of diseases such as cancer and RASopathies.
